دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 30,000,000 تومان- قیمت ویژه : 6,250,000تومان
دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 3,000,000 تومان- قیمت ویژه : 1,250,000تومان
The challenge of shoulder dystocia prevention and the Big Baby trial
Obicetrapib–ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease
Advancing health-care equity for autistic people: mental health as a key priority
Accelerating vaccine development in Africa: lessons from HIV research
The Global North is increasingly unsafe for global health meetings
The UK Supreme Court's ruling and the rights of transgender people
Medicaid cuts, mortality, and health-care expenditure in the USA
From disappointment to despair: USAID cuts to Myanmar's HIV services
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage
Traditional Chinese medicine for acute intracerebral haemorrhage – Authors' reply
Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial
Opportunities for chronic pain self-management: core psychological principles and neurobiological underpinnings
SPIRIT 2025 statement: updated guideline for protocols of randomised trials
